ArticleBMC palliative care2026
Identifying palliative care needs in children with acute lymphoblastic leukemia: validation of the Chinese paediatric palliative screening scale (C-PaPaS).
Article in BMC palliative care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundTimely identification of pediatric palliative care (PPC) needs is essential to improving the quality of life for children with life-threatening illnesses. The Paediatric Palliative Screening Scale (PaPaS) has been validated internationally, but it has not yet been evaluated in mainland China, where PPC infrastructure remains limited and fragmented. The aim of this study is to adapt the PaPaS into Chinese and evaluate its diagnostic performance in identifying PPC needs among children with acute lymphoblastic leukemia (ALL) during induction chemotherapy.
methodsThis retrospective diagnostic accuracy study included children aged 0–18 years newly diagnosed with ALL who initiated induction therapy under the CCCG-ALL-2020 protocol at a tertiary pediatric hospital in China (August 2020–August 2023). The Chinese version of the PaPaS (C-PaPaS) was developed through forward–backward translation and expert review. Scores were retrospectively assigned using electronic medical records. Receiver operating characteristic (ROC) analysis was used to assess diagnostic performance and identify the optimal cutoff.
resultsAmong 153 patients, 28.1% received PPC interventions. Median C-PaPaS scores were significantly higher in the PPC group (23 [IQR 17–25]) than in the non-PPC group (15 [14–19]; P < 0.001). At a cutoff score of > 22, the C-PaPaS demonstrated high sensitivity (93.0%) and moderate specificity (41.8%), with an area under the ROC curve of 0.79 (95% CI: 0.71–0.87).
conclusionsThe C-PaPaS demonstrated strong sensitivity and moderate discriminative accuracy in identifying PPC needs among children with ALL. It may serve as a useful triage tool to support early palliative integration, especially in settings with limited PPC infrastructure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.